Anti-Integrin Therapy for Multiple Sclerosis
Autoimmune Diseases · 2012
DOI: 10.1155/2012/357101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Autoimmune Diseases, 2012. Verfasst von Eiji Kawamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu 514-8507, Japan. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Integrins are the foremost family of cell adhesion molecules that regulate immune cell trafficking in health and diseases. Integrin alpha4 mediates organ-specific migration of immune cells to the inflamed brain, thereby playing the critical role in the pathogenesis of multiple sclerosis. Anti-alpha4 integrin therapy aiming to block infiltration of autoreactive lymphocytes to the inflamed brain has been validated in several clinical trials for the treatment of multiple sclerosis. This paper provides readers with an overview of the molecular and structural bases of integrin activation as well as rationale for using anti-alpha4 integrin therapy for multiple sclerosis and then chronicles the rise and fall of this treatment strategy using natalizumab, a humanized anti-alpha4 integrin.
Autor:innen und Institutionen
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu 514-8507, Japan.
Zitieren
APA
Kawamoto, E., Nakahashi, S., Okamoto, T., Imai, H., & Shimaoka, M. (2012). Anti-Integrin Therapy for Multiple Sclerosis. Autoimmune Diseases. https://doi.org/10.1155/2012/357101
Vancouver
Kawamoto E, Nakahashi S, Okamoto T, Imai H, Shimaoka M. Anti-Integrin Therapy for Multiple Sclerosis. Autoimmune Diseases. 2012. doi:10.1155/2012/357101
BibTeX
@article{Kawamoto2012,
author = {Kawamoto, Eiji and Nakahashi, Susumu and Okamoto, Takayuki and Imai, Hiroshi and Shimaoka, Motomu},
title = {Anti-Integrin Therapy for Multiple Sclerosis},
journal = {Autoimmune Diseases},
year = {2012},
doi = {10.1155/2012/357101}
}
EUVIMED